Literature DB >> 12420727

Molecular therapies in Crohn's disease: coming of age.

S Schreiber.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12420727     DOI: 10.1007/s00384-002-0422-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


× No keyword cloud information.
  10 in total

1.  Etiology of inflammatory bowel syndrome.

Authors:  A Raedler
Journal:  Int J Colorectal Dis       Date:  2001-09       Impact factor: 2.571

2.  Animal models: are they useful for the investigation of gastrointestinal disease?

Authors:  S Schreiber
Journal:  Int J Colorectal Dis       Date:  2000-06       Impact factor: 2.571

3.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

4.  Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.

Authors:  S Schreiber; M Campieri; J F Colombel; S J van Deventer; B Feagan; R Fedorak; A Forbes; M Gassull; J P Gendre; R A van Hogezand; R Lofberg; R Modigliani; F Pallone; W Petritsch; C Prantera; D Rampton; F Seibold; M Vatn; M Zeitz; P Rutgeerts
Journal:  Int J Colorectal Dis       Date:  2001-02       Impact factor: 2.571

Review 5.  Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease.

Authors:  S Wirtz; M F Neurath
Journal:  Int J Colorectal Dis       Date:  2000-06       Impact factor: 2.571

6.  Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats.

Authors:  F Kullmann; H Messmann; M Alt; V Gross; T Bocker; J Schölmerich; J Rüschoff
Journal:  Int J Colorectal Dis       Date:  2001-08       Impact factor: 2.571

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Mechanisms in failure of infliximab for Crohn's disease.

Authors:  S Nikolaus; A Raedler; T Kühbacker; N Sfikas; U R Fölsch; S Schreiber
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

9.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.